4521.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Stats
Объем за сегодня	132 500
Средний объем	119 788
Рыночная капитализация	129.02B
EPS	¥0 ( 2024-02-05 )
Дата следующего отчета о доходах	( ¥0 ) 2024-05-07
Last Dividend	¥75.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	43.29
ATR14	¥1.066 (0.03%)

Объем Корреляция

Длинно: -0.19 (neutral)

Кратко: -0.94 (very strong negative)

Signal:(46.519) Neutral

Kaken Pharmaceutical Co., Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Kaken Pharmaceutical Co., Корреляция - Валюта/Сырье

-0.23
( neutral )

-0.28
( neutral )

-0.44
( neutral )

-0.58
( weak negative )

-0.30
( neutral )

0.63
( weak )

Kaken Pharmaceutical Co., Финансовые показатели

Annual	2022
Выручка:	¥72.98B
Валовая прибыль:	¥39.56B (54.20 %)
EPS:	¥144.79

FY	2022
Выручка:	¥72.98B
Валовая прибыль:	¥39.56B (54.20 %)
EPS:	¥144.79

FY	2022
Выручка:	¥76.03B
Валовая прибыль:	¥41.58B (54.68 %)
EPS:	¥251.43

FY	2021
Выручка:	¥74.98B
Валовая прибыль:	¥40.91B (54.56 %)
EPS:	¥347.37

Financial Reports:

No articles found.

Kaken Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥75.00 (N/A)	¥0 (N/A)	¥75.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Kaken Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 2.37 - Decrease likely (52.58%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.50	2001-03-27
Last Dividend	¥75.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥1 874.70	--
Avg. Dividend % Per Year	0.00%	--
Score	3.32	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	2.37
Div. Directional Score	6.19	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.32

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8125.T	Ex Dividend Knight	2024-02-28	Annually	0.00%
7463.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6678.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6023.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4716.T	Ex Dividend Junior	2023-05-30	Annually	0.00%
3946.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3168.T	Ex Dividend Junior	2023-08-30	Semi-Annually	0.00%
2150.T	Ex Dividend Knight	2023-12-29	Annually	0.00%
9031.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7917.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0411	1.500	9.18	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0176	1.200	9.41	10.00	[0 - 0.3]
returnOnEquityTTM	0.0214	1.500	-0.873	-1.310	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	5.64	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.64	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.63	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0229	-1.500	9.62	-10.00	[0 - 0.6]
interestCoverageTTM	248.72	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	145.29	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	145.29	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0275	-1.500	9.89	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.539	1.000	4.35	4.35	[0.2 - 0.8]
operatingProfitMarginTTM	0.0621	1.000	-0.758	-0.758	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.429	1.000	3.17	3.17	[0.2 - 2]
assetTurnoverTTM	0.428	0.800	-0.478	-0.382	[0.5 - 2]
Total Score				10.01

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	43.50	1.000	5.71	0	[1 - 100]
returnOnEquityTTM	0.0214	2.50	-0.561	-1.310	[0.1 - 1.5]
freeCashFlowPerShareTTM	145.29	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	4.40	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	145.29	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.026	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0763	1.000	-0.592	0	[0.1 - 0.5]
Total Score				2.37

Kaken Pharmaceutical Co.,

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.